Loading…
Emcure Pharmaceuticals (EMCURE)₹2,216−2.80%Pharmaceuticals
At the end of the Jun 2026 quarter, Emcure Pharmaceuticals' shareholders were: promoters 77.86%, FIIs 4.86%, DIIs 8.43%, public 8.85%. Promoter holding is down 0.04 percentage points from 77.90% a quarter earlier. FII holding is up 2.01 percentage points from 2.85% a year earlier. 0.04% of promoter shares were pledged. It had 1,24,986 shareholders.
As of · Company filings (shareholding pattern)
| Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Promoters | 78.11% | 77.97% | 77.95% | 77.95% | 77.91% | 77.90% | 77.90% | 77.86% |
| FIIs | 2.90% | 3.04% | 3.05% | 2.85% | 3.28% | 3.58% | 3.34% | 4.86% |
| DIIs | 3.94% | 3.85% | 3.42% | 2.83% | 4.34% | 6.07% | 6.07% | 8.43% |
| Public | 15.05% | 15.14% | 15.58% | 16.37% | 14.47% | 12.45% | 12.69% | 8.85% |
| Promoter shares pledged | — | — | — | — | — | — | — | 0.04% |
| Number of shareholders | 1,52,908 | 1,43,443 | 1,39,665 | 1,33,543 | 1,26,164 | 1,18,858 | 1,22,184 | 1,24,986 |
| Holder | Category | Jun 2026 | Change (pp) |
|---|---|---|---|
| Satish R Mehta | Promoter | 39.80% | −0.02 |
| Everest Trust (Shares held by Sanjay Rajanikant Mehta with Sonali Sanjay Mehta, as trustees) | Promoter | 7.69% | −0.01 |
| Unity Trust (Shares held by Sunil Rajanikant Mehta with Kamini Sunil Mehta, as trustees) | Promoter | 7.64% | 0.00 |
| Samit Satish Mehta | Promoter | 7.18% | 0.00 |
| Bhavana Satish Mehta | Promoter | 4.67% | 0.00 |
| Namita Vikas Thapar | Promoter | 2.69% | 0.00 |
| Pushpa Rajnikant Mehta | Promoter | 2.07% | 0.00 |
| Sanjay Rajanikant Mehta | Promoter | 1.96% | 0.00 |
| Kotak Midcap Fund | DII | 1.92% | New |
| Sunil Rajanikant Mehta | Promoter | 1.49% | 0.00 |
| Aditya Birla Sun Life Trustee Private Limited A/C - Aditya Birla Sun Life Elss Tax Saver Fund | DII | 1.43% | +0.13 |
| Nippon Life India Trustee Ltd-A/C Nippon India Multi Cap Fund | DII | 1.34% | −0.62 |
| Government Pension Fund Global | FII | 1.04% | New |
| Hdfc Life Insurance Company Limited | DII | 1.04% | New |
| Kamini Sunil Mehta | Promoter | 0.88% | 0.00 |
| Niraj Sunil Mehta | Promoter | 0.58% | 0.00 |
| Rutav Sunil Mehta | Promoter | 0.52% | 0.00 |
| Vikas M Thapar | Promoter | 0.34% | 0.00 |
| Surekha Umakant Shah | Promoter | 0.17% | 0.00 |
| Shah Suhasini Saumil | Promoter | 0.07% | 0.00 |
| Girishchandr Harrai Maganlal Desai | Promoter | 0.06% | 0.00 |
| Smita Paresh Shah | Promoter | 0.06% | 0.00 |
| Shaila Sharad Gujar | Promoter | 0.04% | 0.00 |
| Swati Hetalkumar Shah | Promoter | 0.03% | 0.00 |
| Ranjanakumari Mukeshbhai Desai | Promoter | 0.02% | 0.00 |
Promoters held 77.86% of Emcure Pharmaceuticals at the end of the Jun 2026 quarter, down 0.09 percentage points from 77.95% a year earlier.
In the Jun 2026 quarter, foreign institutional investors (FIIs) held 4.86% (up 1.52 percentage points from 3.34% a quarter earlier) and domestic institutions (DIIs) held 8.43% (up 2.36 percentage points from 6.07% a quarter earlier).
Yes. 0.04% of promoter shares were pledged at the end of the Jun 2026 quarter.
Emcure Pharmaceuticals had 1,24,986 shareholders at the end of the Jun 2026 quarter, against 1,33,543 a year earlier.
Kotak Midcap Fund (DII) held 1.92% at the end of the Jun 2026 quarter, the largest named holding outside the promoter group.